NUVL vs. TEVA, SMMT, GMAB, ITCI, VTRS, MRNA, RDY, PCVX, SRPT, and QGEN
Should you be buying Nuvalent stock or one of its competitors? The main competitors of Nuvalent include Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Intra-Cellular Therapies (ITCI), Viatris (VTRS), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Vaxcyte (PCVX), Sarepta Therapeutics (SRPT), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry.
Nuvalent vs.
Teva Pharmaceutical Industries (NYSE:TEVA) and Nuvalent (NASDAQ:NUVL) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability, community ranking and analyst recommendations.
Teva Pharmaceutical Industries currently has a consensus price target of $23.57, indicating a potential upside of 40.77%. Nuvalent has a consensus price target of $112.36, indicating a potential upside of 41.25%. Given Nuvalent's higher possible upside, analysts clearly believe Nuvalent is more favorable than Teva Pharmaceutical Industries.
Nuvalent has a net margin of 0.00% compared to Teva Pharmaceutical Industries' net margin of -9.91%. Teva Pharmaceutical Industries' return on equity of 42.46% beat Nuvalent's return on equity.
In the previous week, Teva Pharmaceutical Industries had 18 more articles in the media than Nuvalent. MarketBeat recorded 21 mentions for Teva Pharmaceutical Industries and 3 mentions for Nuvalent. Teva Pharmaceutical Industries' average media sentiment score of 0.88 beat Nuvalent's score of 0.00 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.
Teva Pharmaceutical Industries received 1288 more outperform votes than Nuvalent when rated by MarketBeat users. However, 78.18% of users gave Nuvalent an outperform vote while only 67.87% of users gave Teva Pharmaceutical Industries an outperform vote.
54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 97.3% of Nuvalent shares are owned by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are owned by insiders. Comparatively, 12.5% of Nuvalent shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Nuvalent has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Nuvalent is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.
Teva Pharmaceutical Industries has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500. Comparatively, Nuvalent has a beta of 1.38, suggesting that its stock price is 38% more volatile than the S&P 500.
Summary
Nuvalent beats Teva Pharmaceutical Industries on 9 of the 17 factors compared between the two stocks.
Get Nuvalent News Delivered to You Automatically
Sign up to receive the latest news and ratings for NUVL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nuvalent Competitors List
Related Companies and Tools
This page (NASDAQ:NUVL) was last updated on 2/21/2025 by MarketBeat.com Staff
